Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

Key facts

Sponsor

Pfizer

Principal Investigator

Pfizer CT.gov Call Center

Pfizer

Intervention

Xeljanz(drug)

Enrollment

10 enrolled

Eligibility

2-17 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Pfizer, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07386587
  Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
  University of Child Health Sciences and Children's Hospital, Lahore
• RECRUITINGPHASE3NCT06654882
  Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
  Duke University
• RECRUITINGNCT07243782
  Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
  Novartis Pharmaceuticals
• RECRUITINGNANCT07217782
  Pain in Juvenile Arthritis
  Washington University School of Medicine
• RECRUITINGNCT07185750
  Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients
  Hacettepe University
• RECRUITINGNANCT07234747
  Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis
  Istanbul University - Cerrahpasa
• RECRUITINGNCT06806774
  Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic Arthritis
  Hacettepe University
• RECRUITINGNANCT06474546
  Feasibility of a Diet Intervention for Juvenile Arthritis
  The Hospital for Sick Children

See all trials for Juvenile idiopathic arthritis →